Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

New antibody can reduce swelling attacks in patients with hereditary angioedema

New antibody can reduce swelling attacks in patients with hereditary angioedema

New method could improve outcome of leukemia patients receiving stem-cell transplants

New method could improve outcome of leukemia patients receiving stem-cell transplants

NIH-funded study finds how hantaviruses infect the lungs

NIH-funded study finds how hantaviruses infect the lungs

Vanderbilt researchers isolate antibody that can neutralize West Nile virus

Vanderbilt researchers isolate antibody that can neutralize West Nile virus

Study reveals impact of residual inflammatory risk on clinical outcomes after PCI

Study reveals impact of residual inflammatory risk on clinical outcomes after PCI

New first-line treatment for peripheral T-cell lymphoma approved by FDA

New first-line treatment for peripheral T-cell lymphoma approved by FDA

Scientists harness power of natural killer cells to treat children with neuroblastoma

Scientists harness power of natural killer cells to treat children with neuroblastoma

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

Research holds promise for treatment of pediatric brain cancer

Research holds promise for treatment of pediatric brain cancer